Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 2
2009 5
2010 18
2011 11
2012 3
2013 5
2014 3
2015 6
2016 4
2017 3
2018 7
2019 8
2020 12
2021 6
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean samanta kumar pal (1 results)?
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Clinical Trial.
The Gut Microbiome and Metastatic Renal Cell Carcinoma.
Meza L, Feng M, Lee K, Sperandio R, Pal SK. Meza L, et al. Among authors: pal sk. J Clin Med. 2023 Feb 14;12(4):1502. doi: 10.3390/jcm12041502. J Clin Med. 2023. PMID: 36836036 Free PMC article.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Pal SK, et al. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099926 Clinical Trial.
Fighting the 'tobacco epidemic' - A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer.
Cacciamani GE, Matulewicz RS, Kumar R, Teoh JY, Mari A, Pradere B, Gomez Rivas J, Necchi A, Kumar Pal S, Ribal MJ, Shariat S, Rink M; SMART (Stop sMoking for Advance Rehabilitation Treatments) Urology Working Group. Cacciamani GE, et al. Among authors: kumar pal s. Urol Oncol. 2021 Dec;39(12):793-796. doi: 10.1016/j.urolonc.2021.08.025. Epub 2021 Oct 8. Urol Oncol. 2021. PMID: 34629283
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Piha-Paul SA, Azaro A, Arkenau HT, Oh DY, Galsky MD, Pal SK, Hamada K, He Y, Yamamiya I, Benhadji KA, Hollebecque A. Piha-Paul SA, et al. Among authors: pal sk. Invest New Drugs. 2021 Oct;39(5):1324-1334. doi: 10.1007/s10637-021-01104-7. Epub 2021 Mar 27. Invest New Drugs. 2021. PMID: 33774767 Free PMC article. Clinical Trial.
85 results